Department of Human Genetics, University of Michigan, Ann Arbor, MI, USA.
Department of Anesthesiology, University of Virginia, Charlottesville VA, USA.
Brain. 2019 Feb 1;142(2):362-375. doi: 10.1093/brain/awy324.
De novo mutations of the sodium channel gene SCN8A result in an epileptic encephalopathy with refractory seizures, developmental delay, and elevated risk of sudden death. p.Arg1872Trp is a recurrent de novo SCN8A mutation reported in 14 unrelated individuals with epileptic encephalopathy that included seizure onset in the prenatal or infantile period and severe verbal and ambulatory comorbidities. The major biophysical effect of the mutation was previously shown to be impaired channel inactivation accompanied by increased current density. We have generated a conditional mouse mutation in which expression of this severe gain-of-function mutation is dependent upon Cre recombinase. Global activation of p.Arg1872Trp by EIIa-Cre resulted in convulsive seizures and lethality at 2 weeks of age. Neural activation of the p.Arg1872Trp mutation by Nestin-Cre also resulted in early onset seizures and death. Restriction of p.Arg1872Trp expression to excitatory neurons using Emx1-Cre recapitulated seizures and juvenile lethality between 1 and 2 months of age. In contrast, activation of p.Arg1872Trp in inhibitory neurons by Gad2-Cre or Dlx5/6-Cre did not induce seizures or overt neurological dysfunction. The sodium channel modulator GS967/Prax330 prolonged survival of mice with global expression of R1872W and also modulated the activity of the mutant channel in transfected cells. Activation of the p.Arg1872Trp mutation in adult mice was sufficient to generate seizures and death, indicating that successful therapy will require lifelong treatment. These findings provide insight into the pathogenic mechanism of this gain-of-function mutation of SCN8A and identify excitatory neurons as critical targets for therapeutic intervention.
钠离子通道基因 SCN8A 的新生突变导致难治性癫痫脑病,伴有发育迟缓,以及突然死亡的风险增加。p.Arg1872Trp 是一种反复出现的 SCN8A 新生突变,已在 14 名无关个体的癫痫脑病中报道,包括产前或婴儿期发病和严重的言语和运动合并症。该突变的主要生物物理效应先前显示为通道失活受损,伴有电流密度增加。我们已经产生了一种条件性小鼠突变,其中该严重功能获得性突变的表达依赖于 Cre 重组酶。EIIa-Cre 对 p.Arg1872Trp 的全局激活导致了 2 周龄时的惊厥性癫痫发作和致死性。Nestin-Cre 对 p.Arg1872Trp 突变的神经激活也导致了早期发作和死亡。使用 Emx1-Cre 将 p.Arg1872Trp 表达限制在兴奋性神经元中,在 1 至 2 月龄时重现了癫痫发作和青少年致死性。相比之下,Gad2-Cre 或 Dlx5/6-Cre 激活抑制性神经元中的 p.Arg1872Trp 并未引起癫痫发作或明显的神经功能障碍。钠离子通道调节剂 GS967/Prax330 延长了全身性表达 R1872W 的小鼠的存活时间,并且还调节了转染细胞中突变通道的活性。成年小鼠中 p.Arg1872Trp 突变的激活足以引发癫痫发作和死亡,表明成功的治疗将需要终身治疗。这些发现提供了对 SCN8A 这种功能获得性突变的致病机制的深入了解,并确定兴奋性神经元是治疗干预的关键靶点。